Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
100%
Direct Oral Anticoagulant
54%
Anticoagulant Agent
46%
Bleeding
35%
Antiplatelet
33%
Disease
31%
Acute Coronary Syndrome
31%
Atrial Fibrillation
27%
Clopidogrel
24%
Clinical Trial
24%
Rivaroxaban
22%
Pharmacodynamics
22%
Warfarin
21%
Pharmacokinetics
20%
Acetylsalicylic Acid
20%
Ticagrelor
19%
Observational Study
17%
Antithrombocytic Agent
16%
Brain Hemorrhage
15%
Prasugrel
14%
Fondaparinux
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
13%
Antivitamin K
13%
Hip Fracture
12%
Stable Angina Pectoris
12%
Sepsis
12%
Prothrombin Complex
12%
Andexanet Alfa
12%
Heparin
12%
Thromboembolism
11%
Cardiovascular Disease
11%
Blood Clotting Factor 10a Inhibitor
10%
Pharmacotherapy
10%
Apixaban
10%
Ciclonicate
10%
Artery Thrombosis
10%
Statin (Protein)
9%
Fibrinogen Receptor
9%
Vein Thrombosis
9%
Thienopyridine
9%
Low Molecular Weight Heparin
8%
Adverse Event
8%
Cangrelor
8%
Blood Clotting Factor 10a
8%
Dabigatran
8%
Coronary Artery Disease
8%
Betrixaban
7%
Randomized Controlled Trial
7%
Enoxaparin
7%
Ischemia
7%
Medicine and Dentistry
Venous Thromboembolism
39%
Anticoagulation
36%
Acute Coronary Syndrome
24%
Clinician
20%
COVID-19
18%
Antiplatelet
16%
Direct Oral Anticoagulant
14%
Intensive Care Unit
12%
Coronary Artery Disease
12%
Stable Angina
12%
Prothrombin Complex
12%
Health Care Cost
12%
Health Care
11%
Clinical Trial
11%
Antiplatelet Drug
9%
Bleeding
9%
Fibrinogen Receptor
9%
Cardiovascular Disease
9%
Extracorporeal Membrane Oxygenation
8%
Anticoagulant Therapy
8%
Acetylsalicylic Acid
8%
Cangrelor
8%
Ranolazine
7%
Thromboprophylaxis
7%
Antithrombotic Therapy
7%
Receptor
7%
Ticagrelor
7%
Clopidogrel
7%
Platelet
7%
Drug Therapy
7%
Percutaneous Coronary Intervention
6%
Drug-Eluting Stent
6%
Major Bleeding
6%
Secondary Prevention
6%
Patient with Type 2 Diabetes
6%
Randomized Clinical Trial
6%
ST Elevation
6%
Valve Replacement
6%
Percutaneous Aortic Valve Replacement
6%
Ischemia
6%
Cardioversion
6%
Restenosis
6%
Thrombocyte Aggregation
6%
Coagulopathy
6%
Maturity Onset Diabetes of the Young
6%
Andexanet Alfa
6%
Blood Clotting Factor 10a Inhibitor
6%
Platelet Reactivity
6%
Glycoprotein IIb/IIIa Inhibitors
6%
Cardiovascular System
6%
Keyphrases
Venous Thromboembolism
38%
Direct Oral Anticoagulants
20%
Venous Thromboembolism Prevention
19%
Warfarin
15%
Venous Thromboembolism Prophylaxis
15%
Pharmacology
14%
Rivaroxaban
13%
Anticoagulation
12%
Ticagrelor
12%
Bleeding
10%
Unfractionated Heparin
10%
Non-valvular Atrial Fibrillation
9%
COVID-19
9%
Pharmacodynamics
9%
Anticoagulants
8%
Renal Impairment
8%
Medically Ill Patients
8%
Medical Patients
7%
Antithrombotic Therapy
7%
Oral Anticoagulants
7%
Stroke Prevention in Atrial Fibrillation
7%
Thromboprophylaxis
7%
Atrial Fibrillation
6%
Extended Prophylaxis
6%
Coagulopathy
6%
Acquisition Cost
6%
Hospital Acquisition
6%
Antibiotic Costs
6%
Time Management
6%
Acute Disease
6%
Oral Anticoagulant Therapy
6%
Oral Factor Xa Inhibitors
6%
Antithrombotic Agents
6%
Case-based Approach
6%
Andexanet Alfa
6%
Prothrombin Complex Concentrate
6%
Intermediate Dose
6%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
6%
Native American
6%
CYP2C19
6%
Aspirin
6%
Variant Allele
6%
Transcatheter Aortic Valve Replacement
6%
Clopidogrel
6%
Antiplatelet Therapy
6%
At-risk
6%
Backward Navigation
6%
High-fat Meal
6%
Ximelagatran
6%
Renal Function
6%
